Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615653 · ClinicalTrials.gov registry record · NA
EUS Guided Celiac Neurolysis
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 110
- Enrollment target
NCT01615653: Completed NA study, sponsored by Mayo Clinic.
NCT01615653 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01615653, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
Study Summary
* Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal thereby only briefly remaining in contact with neural structures and limiting the degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result in diminished neurolysis and decrease efficacy.
Interventions
- PROCEDURE EUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01615653
The ClinicalTrials.gov registry entry for NCT01615653 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EUS is the first listed.
NCT01615653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01615653 about?
NCT01615653 is a clinical study titled "EUS Guided Celiac Neurolysis". * Hypothesis: \- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the efficacy of neurolysis and subsequent pain control and survival in patients with pancreatic carcinoma. * Rationale: * Standard CPN leads to inaccurate delivery of the injectate with rapid disper...
What is the current status of trial NCT01615653?
This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2009-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01615653?
The interventions under investigation include: EUS (PROCEDURE).
Who is sponsoring clinical trial NCT01615653?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.